How Much Does Saxenda Cost in Maryland in 2026?

Maryland Retail Pricing for Saxenda

The average cash price at Maryland retail pharmacies sits at $1,349 per month in 2026, matching Novo Nordisk's wholesale acquisition cost. That figure covers five pre-filled 6 mg/mL pens, which supply roughly 30 days at the maintenance dose of 3 mg daily. Prices do not vary dramatically across the state. A pharmacy in Baltimore, Bethesda, or Cumberland will quote within a narrow band of that list price because Novo Nordisk's WAC anchors the floor.

Without insurance or discount programs, Maryland residents face one of the higher monthly outlays for any FDA-approved anti-obesity medication. The FDA-approved prescribing information for Saxenda confirms the drug is indicated as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. Because the drug requires indefinite use to maintain weight loss, annual costs can exceed $16,000 at full retail.

Price-comparison tools like GoodRx and RxSaver sometimes surface coupons that bring the out-of-pocket cost to $1,000 to $1,200 at specific Maryland chains. These coupons cannot be combined with federal healthcare programs such as Medicare Part D or Medicaid.

What the SCALE Trial Showed About Liraglutide 3 mg

Clinical evidence behind Saxenda comes primarily from the SCALE Obesity and Prediabetes trial, a 56-week, double-blind, randomized study published in the New England Journal of Medicine. The trial enrolled 3,731 adults without diabetes who had a BMI of 30 or greater (or 27 or greater with dyslipidemia or hypertension). Participants receiving liraglutide 3 mg lost a mean of 8.0% of body weight compared with 2.6% for placebo [1]. More than 63% of liraglutide-treated patients achieved at least 5% weight loss versus 27% on placebo.

The trial also demonstrated a 79% reduction in progression from prediabetes to type 2 diabetes over 56 weeks in the liraglutide group [1]. That finding matters for Maryland residents with prediabetes who are evaluating whether the drug's cost is justified by long-term metabolic benefits.

Dr. Xavier Pi-Sunyer, lead author of the SCALE trial, stated: "Treatment with liraglutide 3.0 mg, as an adjunct to diet and exercise, was associated with clinically meaningful weight loss" [1]. This direct connection between the trial evidence and chronic disease prevention is one reason insurers increasingly, if reluctantly, add anti-obesity medications to their formularies.

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends considering anti-obesity pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with complications, noting that "the benefits of medications that have been approved must be weighed against their potential risks" (Endocrine Society guideline) [2].

Maryland Medicaid Coverage for Saxenda

Maryland Medicaid covers Saxenda with prior authorization. That single word, "prior," is where most denials originate. The prior authorization process typically requires documentation that the patient has a qualifying BMI, has attempted lifestyle modification (usually for 3 to 6 months), and has at least one weight-related comorbidity.

Providers submitting PA requests in Maryland should include recent lab work (fasting glucose, HbA1c, lipid panel), a record of dietary counseling or referral, and the patient's BMI trajectory. Denials can be appealed through the state's fair hearing process.

Maryland's Medicaid managed care organizations (MCOs), including CareFirst, Priority Partners, and Amerigroup, each maintain their own formulary committees, so coverage details may differ slightly between plans. Patients enrolled in HealthChoice (Maryland's Medicaid managed care program) should contact their specific MCO for formulary placement and step-therapy requirements.

A practical note: Maryland Medicaid cannot be combined with the Novo Nordisk savings card. Patients on Medicaid who receive approval pay $0 to minimal copays depending on their plan tier. For those who are denied, the appeal success rate improves substantially when the prescribing clinician includes a letter of medical necessity citing the SCALE trial data and the patient's specific comorbidity profile [1].

Commercial Insurance Coverage in Maryland

Among Maryland's major commercial insurers, coverage varies. CareFirst BlueCross BlueShield, the state's largest commercial carrier, has added several GLP-1 receptor agonists to its pharmacy benefit, though Saxenda specifically may sit on a higher formulary tier or require step therapy through orlistat first. United Healthcare, Aetna, and Cigna plans sold through the Maryland Health Benefit Exchange each set their own prior authorization criteria.

The general pattern across most Maryland commercial plans follows a predictable sequence. First, the insurer requires documented BMI ≥30 (or ≥27 with comorbidity). Second, the patient must have tried and failed a lower-cost intervention, which could mean 3 to 6 months of documented lifestyle changes, or in some plans, a trial of orlistat. Third, the prescriber submits a PA with supporting records.

Out-of-pocket costs for commercially insured Maryland patients who clear PA range from $50 to $300 per month depending on formulary tier, deductible status, and plan design. Specialty tier placement pushes costs higher. Patients whose plans place Saxenda on a non-preferred specialty tier may face coinsurance of 25% to 40%, translating to $337 to $540 monthly before the Novo Nordisk savings card is applied.

The Centers for Disease Control and Prevention reports that 33.9% of Maryland adults have obesity [3], a figure that creates substantial actuarial pressure on the state's insurers but also an economic argument for coverage: treating obesity-related complications costs far more than prevention.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card for Saxenda that reduces the monthly copay to as low as $25 for eligible commercially insured patients. The card covers up to $200 off each 30-day prescription fill. It works at virtually every retail pharmacy in Maryland, including CVS, Walgreens, Rite Aid, Giant, and Safeway locations.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Saxenda (even partially), must not be enrolled in any federal or state government-funded healthcare program (Medicare, Medicaid, TRICARE, VA), and must be a U.S. resident age 18 or older. The card resets annually and has a maximum annual benefit, which Novo Nordisk adjusts periodically.

For Maryland patients whose commercial insurance covers Saxenda at a preferred brand tier with a $75 copay, the savings card reduces the out-of-pocket cost to $25 per month, or $300 per year. For patients facing a $350 coinsurance charge on a specialty tier, the card brings the monthly cost to $150. The savings card does not reduce the cost below $25 per fill.

Patients should be aware that savings card benefits do not count toward their plan's deductible or out-of-pocket maximum. This means using the card may delay reaching the threshold where insurance covers the drug at 100%.

Compounded Liraglutide 3 mg in Maryland

Compounded liraglutide 3 mg is available in Maryland through licensed 503A compounding pharmacies. These pharmacies operate under the Federal Food, Drug, and Cosmetic Act, Section 503A, which permits patient-specific compounding based on a valid prescription. Maryland's Board of Pharmacy oversees state-level compliance for compounding pharmacies operating within its borders.

The legal framework is worth understanding. A 503A pharmacy compounds an individual prescription from a licensed prescriber for an identified patient. This is distinct from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions. Both pathways are permitted under FDA compounding regulations, but 503A is the more common route for Maryland patients seeking compounded liraglutide [4].

Pricing for compounded liraglutide 3 mg through Maryland 503A pharmacies is substantially lower than brand-name Saxenda. Compounded versions are not AB-rated generics and are not FDA-approved products. They are prepared from bulk pharmaceutical-grade liraglutide API. Quality depends on the specific pharmacy's sourcing, testing, and sterile compounding practices.

Patients considering compounded liraglutide should confirm that the pharmacy holds a valid Maryland Board of Pharmacy compounding permit, uses USP 797-compliant sterile compounding facilities, and provides third-party potency and sterility testing certificates on request. The FDA's guidance on compounding outlines the regulatory boundaries for these preparations [4].

A critical distinction: compounded liraglutide is not the same product as Saxenda. It contains the same active molecule but has not undergone the same manufacturing, stability, or clinical testing process as the branded product.

Telehealth Access to Saxenda in Maryland

Maryland permits telehealth prescribing of Saxenda. A patient can receive an initial evaluation, prescription, and ongoing management entirely through a virtual visit with a Maryland-licensed prescriber. This is relevant because Maryland's geography includes rural areas on the Eastern Shore and in Western Maryland where obesity medicine specialists are scarce.

The Maryland Medical Practice Act, updated during and after the COVID-19 public health emergency, allows audio-video telehealth encounters to establish a patient-provider relationship sufficient for prescribing controlled and non-controlled medications. Saxenda (liraglutide) is not a controlled substance, which simplifies the prescribing pathway.

Several national telehealth platforms that operate in Maryland offer Saxenda consultations. Patients should verify that the platform's prescribers hold active Maryland medical licenses and that the platform coordinates prior authorization with the patient's insurance. Some telehealth platforms also support access to compounded liraglutide through affiliated 503A pharmacies.

In-state telehealth prescribers at academic medical centers, including those affiliated with Johns Hopkins and the University of Maryland Medical System, have launched virtual obesity medicine clinics. These programs offer the advantage of coordinating Saxenda prescriptions with broader metabolic health management, including referral for bariatric surgery evaluation when appropriate. The National Institutes of Health maintains treatment guidelines recommending pharmacotherapy as part of a comprehensive obesity management plan that includes behavioral and dietary interventions [5].

How to Lower Your Saxenda Cost in Maryland

Seven concrete strategies exist for reducing out-of-pocket Saxenda costs in Maryland.

Use the Novo Nordisk savings card. If you have commercial insurance, this is the first step. Potential savings: up to $200 per fill.

Request tier exceptions. If your insurer places Saxenda on a specialty or non-preferred tier, your prescriber can submit a formulary exception request arguing medical necessity. Success rates improve with thorough documentation.

Compare pharmacy prices. Maryland retail pharmacies do not all charge identical cash prices. Independent pharmacies occasionally price below the large chains. Mail-order specialty pharmacies may offer lower per-unit costs for 90-day supplies.

Explore compounded liraglutide. A licensed 503A compounding pharmacy in Maryland can prepare liraglutide 3 mg at a fraction of the branded cost. Discuss this option with your prescriber.

Check for patient assistance programs. Novo Nordisk's patient assistance program (NovoCare) provides Saxenda at no cost to uninsured patients meeting income eligibility criteria, generally at or below 400% of the federal poverty level.

Use an HSA or FSA. Saxenda is an eligible expense for health savings accounts and flexible spending accounts. Paying with pre-tax dollars effectively reduces the cost by your marginal tax rate.

Consider dose optimization. Some patients maintain clinically significant weight loss at 2.4 mg daily rather than the full 3.0 mg dose. This stretches a 30-day pen supply to approximately 37 days, reducing monthly costs by roughly 20%. This requires prescriber approval and monitoring.

Saxenda vs. Other GLP-1 Options Available in Maryland

Maryland patients have access to several GLP-1 receptor agonist options beyond Saxenda. Wegovy (semaglutide 2.4 mg weekly) showed superior weight loss in head-to-head pharmacology comparisons: the STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight loss with semaglutide 2.4 mg versus 2.4% with placebo at 68 weeks [6]. That compares with 8.0% for liraglutide 3 mg in SCALE [1]. The tradeoff: Wegovy's list price is approximately $1,349 per month as well, and supply constraints have been more pronounced.

Zepbound (tirzepatide) represents the dual GIP/GLP-1 receptor agonist class. The SURMOUNT-1 trial (N=2,539) reported mean weight loss of 20.9% at the 15 mg dose over 72 weeks [7]. Zepbound's list price is comparable to Saxenda, but Maryland insurance coverage patterns differ.

For Maryland patients whose primary consideration is cost, the relevant comparison is monthly out-of-pocket after insurance and savings cards. A patient whose commercial plan covers Saxenda at preferred brand tier with a $75 copay pays $25 per month after the savings card. The same patient might face a $300 specialty tier coinsurance for Wegovy, reduced to $100 by Novo Nordisk's savings card. The cheapest option depends entirely on your specific plan's formulary.

Oral semaglutide (Rybelsus, 14 mg) is FDA-approved for type 2 diabetes but prescribed off-label for weight management in some Maryland practices. Its lower list price and oral formulation appeal to needle-averse patients.

The American Association of Clinical Endocrinology (AACE) obesity algorithm recommends selecting anti-obesity pharmacotherapy based on efficacy, side-effect profile, cost, and patient preference rather than defaulting to any single agent [8].